Melatonin

Generic Name: Melatonin

Brand Names: Circadin, Slenyto, Melatonin Neurim

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₂O_₂

CAS Number: 73-31-4

Unique Ingredient Identifier: JL5DK93RCL

Background: Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence ...

Indication: Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for ...

Associated Conditions: Insomnia

Associated Therapies: -

Clinical Trials

Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer

Phase 2

Recruiting

Conditions: Sleep
Anxiety
Depression
Fatigue
Cancer

Interventions: Other: Placebo for Melatonin
Drug: Melatonin
Drug: Methylphenidate

First Posted Date: 2022-07-26

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 188

Registration Number: NCT05474846

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Exogenous Melatonin in Postmenopausal Women With Insomnia

Not Applicable

Recruiting

Conditions: Insomnia

Interventions: Drug: Melatonin
Drug: Placebo

First Posted Date: 2022-07-01

Last Posted Date: 2024-02-20

Lead Sponsor: Douglas Mental Health University Institute

Target Recruit Count: 14

Registration Number: NCT05440734

Locations: 🇨🇦
Centre for Study and Treatment of Circadian Rhythms, Montréal, Quebec, Canada

Getting SMART for Pediatric Epilepsy

Phase 2

Recruiting

Conditions: Epilepsy in Children

Interventions: Drug: Placebo
Drug: Melatonin

First Posted Date: 2022-06-30

Last Posted Date: 2023-09-18

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 120

Registration Number: NCT05439876

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

HD-tDCS Combined With Circadian Rhythm Reconstruction and Micro Expression Changes on Consciousness Recovery in Patients With Chronic Disturbance of Consciousness

Not Applicable

Recruiting

Conditions: Disorder of Consciousness

Interventions: Other: Placebo
Drug: Melatonin
Other: HD-tDCS

First Posted Date: 2022-03-17

Last Posted Date: 2024-06-04

Lead Sponsor: First Affiliated Hospital of Zhejiang University

Target Recruit Count: 90

Registration Number: NCT05285124

Locations: 🇨🇳
First Affiliated Hospital,Zhejiang University, Hanzhou, Zhejiang, China

Study MIPAE - Melatonin and Essential Arterial Hypertension

Phase 2

Active, not recruiting

Conditions: Essential Hypertension

Interventions: Drug: Melatonin

First Posted Date: 2022-02-25

Last Posted Date: 2023-02-01

Lead Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Target Recruit Count: 23

Registration Number: NCT05257291

Locations: 🇮🇹
Anatomy and Physiopathology Division, Department of Experimental and Clinical Sciences, University of Brescia (Italy), Viale Europa 11, 25123 Brescia, Italy, Brescia, Italy

The Efficacy of Oral Melatonin in Preventing Postoperative Delirium for Patients Undergoing Orthopedic Surgery Under General Anesthesia

Not Applicable

Completed

Conditions: Delirium, Anesthesia Emergence
Delirium

Interventions: Other: No intervention
Drug: Midazolam
Drug: Melatonin

First Posted Date: 2022-02-11

Last Posted Date: 2022-02-11

Lead Sponsor: University of Baghdad

Target Recruit Count: 36

Registration Number: NCT05236907

Locations: 🇮🇶
Al-Kadhemya Private Hospital, Baghdad, Iraq
🇮🇶
Ghazi Al-Hariri Teaching Hospital, Baghdad, Iraq

Melatonin vs Pregabalin for Anxiolysis and Sedation

Phase 4

Completed

Conditions: Anxiety

Interventions: Drug: Melatonin
Drug: Pregabalin
Drug: Ondansetron 4 MG

First Posted Date: 2022-02-02

Last Posted Date: 2022-12-21

Lead Sponsor: Menoufia University

Target Recruit Count: 78

Registration Number: NCT05221151

Locations: 🇪🇬
Faculty of Medicine, University Hospitals, Shibīn Al Kawm, Menoufia, Egypt

Effect of Melatonin on Palatal Wound Healing (Randomized Controlled Clinical Trial)

Phase 2

Conditions: Wound Heal

Interventions: Drug: Melatonin
Drug: Carbopol

First Posted Date: 2021-11-16

Last Posted Date: 2022-01-26

Lead Sponsor: Salma Nabil

Target Recruit Count: 26

Registration Number: NCT05122130

Locations: 🇪🇬
Alexandria University, Alexandria, Egypt

Melatonin for Prevention of Kidney Injury

Phase 3

Recruiting

Conditions: Acute Kidney Injury
Adverse Drug Event

Interventions: Other: Placebo Capsule
Drug: Melatonin

First Posted Date: 2021-10-19

Last Posted Date: 2024-11-01

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 300

Registration Number: NCT05084196

Locations: 🇺🇸
Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸
Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States

The Effect of Melatonin in Patients With Low Anterior Resection Syndrome

Phase 2

Active, not recruiting

Conditions: Low Anterior Resection Syndrome

Interventions: Drug: Melatonin
Drug: Placebo

First Posted Date: 2021-09-13

Last Posted Date: 2023-04-25

Lead Sponsor: Ismail Gögenur

Target Recruit Count: 21

Registration Number: NCT05042700

Locations: 🇩🇰
Zealand University Hospital, Køge, Region Sjælland, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy